Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-06 |
2024-03 |
-0.38 |
-0.36 |
0.02 |
5.26% |
2024-03-28 |
2023-12 |
-0.46 |
N/A |
N/A |
N/A |
2024-03-28 |
2023-12 |
-0.46 |
-0.37 |
0.09 |
19.57% |
2023-11-09 |
2023-09 |
-0.56 |
-0.4 |
0.16 |
28.57% |
2023-11-09 |
2023-09 |
-0.56 |
N/A |
N/A |
N/A |
2023-08-03 |
2023-06 |
-0.51 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-08-31 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-08-03 |
Chardan Capital |
Upgrade |
Buy |
Buy |
2023-06-05 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-05-07 |
Chardan Capital |
Upgrade |
|
Buy |
2023-03-30 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2023-03-23 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2021-08-02 |
BERRY DAVID A |
Director |
53.08K |
Purchase |
2023-02-26 |
FLAGSHIP PIONEERING, INC. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
2021-08-02 |
INVUS PUBLIC EQUITIES ADVISORS, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
2022-01-31 |
KARANDE MAHESH |
Chief Executive Officer |
117.71K |
Conversion of Exercise of derivative security |
2021-08-02 |
SAWHNEY ROGER M.D. |
Chief Financial Officer |
2.94K |
Purchase |
2023-06-01 |
YOUNG RICHARD A |
Director |
739.12K |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Flagship Pioneering Inc. |
29.23M |
163.66M |
53.00% |
2023-06-29 |
FMR, LLC |
5.43M |
30.43M |
9.86% |
2023-06-29 |
Harbourvest Partners, LLC |
3.51M |
19.67M |
6.37% |
2023-06-29 |
Artal Group S.A. |
2.53M |
14.19M |
4.59% |
2023-06-29 |
State Of Wisconsin Investment Board |
1.86M |
10.41M |
3.37% |
2023-06-29 |
Blackrock Inc. |
1.61M |
9.01M |
2.92% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-08-30 |
Fidelity Growth Company Fund |
1.58M |
5.78M |
2.86% |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
1.06M |
5.91M |
1.91% |
2023-05-30 |
Fidelity Growth Company K6 Fund |
664.83K |
5.05M |
1.21% |
2023-08-30 |
Fidelity Select Portfolios - Biotechnology |
492.90K |
1.81M |
0.89% |
2023-08-30 |
iShares Russell 2000 ETF |
490.51K |
1.80M |
0.89% |
2023-08-30 |
Fidelity Series Growth Company Fund |
435.68K |
1.60M |
0.79% |